Early Detection of White Matter Integrity Changes in Down Syndrome: The Promise of PSMD as a Sensitive Biomarker

Le résumé fourni par la source

Abstract Background Down syndrome (DS) is a genetic condition associated with an ultra‐high risk of developing Alzheimer's disease (AD). While vascular risk factors (VRF) are less prevalent in DS, radiological hallmarks of small vessel disease (SVD) are commonly observed. The peak width of skeletonized mean diffusivity (PSMD) is a diffusion tensor imaging (DTI) marker designed to quantify the white matter (WM) damage secondary to cerebral SVD. Here, we aimed to characterize PSMD alterations along the AD continuum in DS and define associations with AD and SVD biomarkers. Method Cross‐sectional study using the Sant Pau Initiative on Neurodegeneration (SPIN) and Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) cohorts. We included 70 euploid healthy controls (HC; median age [IQR]=54.37 [9.03] years, females=70%), and 140 individuals with DS (age=44.15 [17.33] years, females=47.14%), including 92 asymptomatic (aDS), 28 prodromal AD (pDS), and 20 with AD dementia (dDS), underwent a 3T‐MRI protocol. DTI images were visually inspected, and PSMD was extracted using a fully automated pipeline (Baykara et al., 2016). Non‐parametric tests were used to assess the effect of sociodemographic (age, sex, intellectual disability) and genetic (APOE haplotype) factors, VRF (hypertension, dyslipidemia, diabetes mellitus), and AD disease severity on PSMD. Associations with AD biomarkers (Aβ42/Aβ40 ratio, pTau181, and NfL in cerebrospinal fluid [CSF]) and SVD markers (WM hyperintensities [WMH] and microbleeds) were evaluated. Result PSMD was more strongly associated with age in DS (rho=0.56; p <0.001) than in HC (rho=0.38, p <0.001; Figure 1A), with regression lines starting to diverge at age 42. No significant effects were found for sex, APOEε4 status, intellectual disability, or VRF (Figure 1C‐D‐E). PSMD increased linearly along the AD continuum (HC p = 0.003, Figure 2D) and strongly correlated with WMH (rho=0.56, p <0.001; Figure 2E). Conclusion In DS, PSMD changed approximately 10‐15 years before the onset of AD symptoms and linearly increased with AD clinical stages, AD pathology, and SVD metrics. These findings underscore the potential of PSMD as a sensitive biomarker for detecting early WM alterations in adults with DS.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.